Preclinical Imaging Market Size, Share, Growth, Industry Analysis, Trends and Dynamics, By Types (CT Imaging, MRI Imaging, PET/SPECT Imaging, Multi-modal Imaging, Optical Imaging, Ultrasound Imaging, Photoacoustic Imaging, Reagents, Services), By Applications (Hospital, Diagnostics Center, Others), and Regional Insights and Forecast to 2035

Preclinical Imaging Size

The Preclinical Imaging Market size was USD 2668.96 Million in 2025 and is projected to reach USD 2807.75 Million in 2026 and USD 4430.98 Million by 2035, exhibiting a CAGR of 5.2% during the forecast period 2026-2035.

The Preclinical Imaging Market is advancing as pharmaceutical developers, translational research institutes, hospitals, and specialized laboratories increasingly combine anatomical and molecular imaging in longitudinal animal studies. An estimated 58% of newly configured imaging laboratories favor platforms capable of supporting multiple research workflows, while roughly 43% of advanced studies now incorporate two or more complementary imaging techniques. Demand is shifting from isolated equipment purchases toward integrated research environments combining scanners, image-processing software, reagents, animal handling, and technical services. Buyers increasingly evaluate sensitivity, spatial resolution, scan duration, reproducibility, anesthesia management, and compatibility with therapeutic research before procurement. Oncology, neuroscience, cardiovascular disease, metabolic disorders, and theranostic development remain important workload categories, while artificial intelligence-assisted reconstruction and quantitative analysis are improving laboratory productivity.

The U.S. Preclinical Imaging Market benefits from dense pharmaceutical research infrastructure, university medical centers, contract research organizations, and federally supported biomedical programs. The country is estimated to represent about 29% of global preclinical imaging demand, while nearly 54% of major U.S. imaging laboratories use more than one modality within translational workflows. Demand is particularly strong for MRI, PET/SPECT, micro-CT, ultrasound, optical imaging, and increasingly photoacoustic systems that support repeated measurements without sacrificing study subjects. Purchasing decisions are becoming more centralized, with research institutions emphasizing utilization rates, modular upgrades, shared-core access, and standardized image analysis. U.S. laboratories are also early adopters of multimodal imaging, advanced reconstruction algorithms, quantitative biomarker workflows, and integrated animal monitoring, strengthening the country's role in technology validation and high-complexity preclinical research.

Japan remains an important Asia-Pacific market because of its pharmaceutical research base, imaging engineering capabilities, and established academic biomedical network. Japan is estimated to account for nearly 6% of worldwide preclinical imaging activity, while approximately 47% of advanced research facilities prioritize compact or space-efficient imaging configurations. Demand is supported by neuroscience, oncology, regenerative medicine, cardiovascular research, and molecular imaging programs. Japanese laboratories typically place strong emphasis on reproducibility, low-maintenance operation, precise physiological control, and high-resolution imaging. Increasing interest in integrated PET/CT, MRI-based phenotyping, micro-ultrasound, and optical techniques is also encouraging modernization of shared laboratory infrastructure.

Key Findings

• Market Size: The market increased from 2668.96 Million in 2025 to 2807.75 Million in 2026, is expected to reach 2953.75 Million in 2027, and is forecast to reach 4430.98 Million by 2035, at a CAGR of 5.2%.
• Growth Drivers: Multimodal workflows influence 62% of advanced purchases, while 48% of laboratories prioritize higher sensitivity, longitudinal imaging, automation, and faster reconstruction.
• Trends: Integrated platforms influence 57% of procurement decisions, while approximately 41% of research facilities are increasing adoption of automated quantitative image analysis.
• Key Players: Bruker Corporation, Siemens A.G., General Electric (GE), VisualSonics Inc. (Fujifilm), Mediso Ltd. & more.
• Regional Insights: North America holds 38% market share through mature biomedical research; Europe represents 27%; Asia-Pacific accounts for 25%; Latin America and Middle East & Africa collectively hold 10%.
• Challenges: Capital and infrastructure constraints affect nearly 44% of prospective installations, while 31% of laboratories report difficulties recruiting specialized imaging and analysis personnel.
• Industry Impact: Longitudinal imaging can reduce terminal-study dependence by approximately 34%, while integrated workflows improve experimental data continuity for nearly 46% of complex studies.
• Recent Developments: Approximately 52% of new high-end platforms emphasize multimodality, while 39% of recent laboratory upgrades prioritize software-led reconstruction and quantitative imaging capabilities.

Preclinical imaging operates differently from conventional diagnostic imaging because purchasing decisions are governed by experimental flexibility rather than patient throughput alone. Approximately 49% of sophisticated research groups evaluate equipment according to cross-modality compatibility, while about 36% consider animal transfer, anesthesia continuity, and physiological monitoring major workflow requirements. Buyers increasingly favor modular platforms that can be expanded as research priorities change. Imaging cores also rely on reservation-based utilization models, standardized acquisition protocols, centralized analysis, and shared technical staff. Photoacoustic imaging, molecular PET/SPECT, high-field MRI, micro-ultrasound, and optical imaging are gaining importance where researchers require functional, anatomical, and molecular information from the same experimental cohort.

Preclinical Imaging Market Trends

The Preclinical Imaging Market is moving toward multimodal, quantitative, and longitudinal research environments rather than single-purpose imaging laboratories. Approximately 56% of sophisticated research programs now consider interoperability between imaging techniques an important purchasing criterion, while 42% place increased emphasis on software capable of aligning anatomical, functional, and molecular datasets. This change reflects pressure to extract more information from each study subject and improve reproducibility across experimental stages. High-resolution MRI and micro-CT remain central for anatomy, whereas PET/SPECT and optical systems support molecular tracking. Ultrasound and photoacoustic platforms are becoming more relevant where real-time imaging, vascular assessment, oxygenation mapping, and relatively rapid scanning are required. Vendors are responding with modular configurations, multimodal animal beds, standardized data formats, automated reconstruction, and advanced image-registration tools that reduce workflow fragmentation between instruments.

Another defining trend is the shift from image generation toward quantitative decision support. Roughly 45% of advanced preclinical laboratories are increasing their use of automated segmentation, reconstruction, or image-analysis software, and nearly 33% are integrating imaging biomarkers more systematically into therapeutic evaluation. Researchers increasingly need repeatable measurements of tumor volume, tracer uptake, perfusion, tissue elasticity, oxygen saturation, cardiac function, neurological activity, and treatment response. As study complexity rises, buyers are placing greater weight on software usability, cross-study comparability, and data export alongside traditional hardware specifications. Compact scanners and modular upgrades are also widening access among laboratories that cannot justify large imaging suites. These trends favor suppliers capable of combining instrumentation, applications support, software, accessories, and service into a coordinated research platform.

Preclinical Imaging Market Dynamics

OPPORTUNITY

Expansion of multimodal and translational imaging workflows

The strongest opportunity lies in research environments seeking coordinated anatomical, molecular, functional, and physiological information from the same experimental subject. Approximately 51% of advanced laboratories indicate growing preference for platforms that can connect or combine imaging modalities, while nearly 37% are evaluating modular upgrades instead of completely independent scanners. Multimodal imaging supports longitudinal study design, reduces biological variability between separate animal cohorts, and strengthens correlation between molecular events and anatomical changes. Suppliers that integrate PET, SPECT, CT, MRI, optical imaging, ultrasound, or photoacoustic capabilities with compatible animal handling and analysis software can address increasingly complex therapeutic programs. This creates opportunities for equipment vendors, software developers, reagent suppliers, and technical service providers.

DRIVERS

Rising use of longitudinal imaging in drug and disease research

Longitudinal experimental design is a major structural driver because researchers can follow disease progression or therapeutic response repeatedly within the same subjects. An estimated 59% of high-complexity imaging studies now consider serial measurements important for reducing inter-subject variability, while approximately 40% of laboratories are increasing demand for non-invasive or minimally invasive imaging procedures. This favors MRI, PET/SPECT, ultrasound, optical, CT, and photoacoustic technologies that can provide repeatable measurements throughout research programs. Growing interest in oncology, neuroscience, cardiovascular disease, immunotherapy, metabolic disorders, and theranostics further supports imaging utilization. Demand therefore depends increasingly on reproducibility, animal welfare, quantitative analysis, and efficient cross-timepoint comparison rather than resolution alone.

Market Restraints

"High capital intensity and specialized infrastructure requirements"

Preclinical imaging installations can require shielded rooms, magnetic-field controls, radiation handling, anesthesia infrastructure, specialized computing, and trained technical staff in addition to the scanner itself. Approximately 43% of smaller research organizations identify infrastructure cost as a significant barrier, while close to 29% delay equipment replacement when existing systems remain scientifically usable. High-field MRI, PET/SPECT, and multimodal environments can be particularly demanding because laboratories must coordinate facility engineering, regulatory procedures, isotope handling, animal welfare protocols, and ongoing service. These requirements lengthen procurement cycles and favor shared-core models. Suppliers increasingly respond through compact scanners, modular configurations, service packages, and upgradeable architectures intended to reduce the operational burden of ownership.

Market Challenges

"Complex data integration and shortages of specialized imaging expertise"

The market faces a growing gap between advanced imaging capability and the expertise required to generate reproducible quantitative results. Approximately 35% of research facilities report difficulty maintaining sufficient cross-modality technical expertise, while 27% identify data harmonization as a persistent workflow issue. MRI, CT, PET, SPECT, ultrasound, optical, and photoacoustic systems generate fundamentally different datasets, reconstruction requirements, and quantitative endpoints. Laboratories therefore need personnel who understand animal physiology, acquisition protocols, calibration, statistics, and image analysis rather than instrument operation alone. The challenge becomes more pronounced in multicenter research, where acquisition parameters and software pipelines must remain comparable. Standardized workflows, automated quality control, centralized analysis, and vendor-supported training are consequently becoming more influential in purchasing decisions.

Segmentation Analysis

The Preclinical Imaging Market is segmented by technology and application according to the information each research workflow must capture. Anatomical modalities such as CT and MRI remain foundational, while PET/SPECT, optical imaging, and reagents support molecular characterization. Ultrasound and photoacoustic technologies address dynamic physiology, vascular function, and tissue composition, whereas multimodal configurations connect complementary datasets. Approximately 46% of advanced laboratories use at least two imaging technologies during major research programs, and nearly 32% are increasing reliance on shared imaging cores to improve utilization. Application demand is distributed among hospitals with research programs, diagnostic and translational centers, and other organizations including pharmaceutical laboratories, biotechnology companies, contract research organizations, and academic institutions. Market growth increasingly depends on workflow integration, quantitative analysis, and study-specific flexibility.

By Type

CT Imaging: CT imaging remains an essential anatomical platform for skeletal research, pulmonary studies, oncology, cardiovascular investigations, and anatomical localization. Its rapid acquisition and high spatial resolution make micro-CT particularly useful where researchers need three-dimensional structural information. Approximately 16% of 2026 market demand is allocated to CT imaging, while nearly 44% of multimodal nuclear imaging studies use CT information for anatomical registration or attenuation-related workflows. Development priorities include faster reconstruction, lower radiation exposure, improved soft-tissue contrast, and automated quantitative analysis.

CT Imaging represents approximately USD 449.24 Million in 2026, equal to 16% market share, and is modeled to reach USD 664.65 Million by 2035 at a 4.45% CAGR.

MRI Imaging: MRI Imaging holds a central position in preclinical neuroscience, oncology, cardiovascular research, musculoskeletal studies, and metabolic imaging because it provides strong soft-tissue characterization without ionizing radiation. About 18% of 2026 market demand is associated with MRI, and nearly 39% of high-complexity translational laboratories identify repeatable soft-tissue imaging as a major protocol requirement. High-field systems, cryogenic coils, diffusion imaging, spectroscopy, functional MRI, and hyperpolarized imaging are widening the modality's scientific value, although installation complexity and technical expertise remain significant considerations.

MRI Imaging is estimated at USD 505.39 Million in 2026 with 18% market share and is projected to reach USD 797.58 Million by 2035, corresponding to a 5.20% CAGR.

PET/SPECT Imaging: PET/SPECT Imaging is important for molecular imaging, pharmacokinetics, biodistribution, receptor studies, oncology, neurology, and theranostic development. Approximately 17% of 2026 demand comes from this segment, while nearly 52% of specialized nuclear-imaging laboratories prioritize quantitative tracer sensitivity when evaluating systems. New radionuclides and targeted radiopharmaceutical research are encouraging demand for broader isotope compatibility and improved resolution. Integrated PET/CT, SPECT/CT, and PET/MRI workflows strengthen the segment by combining molecular information with precise anatomical localization.

PET/SPECT Imaging accounts for approximately USD 477.32 Million in 2026 and 17% market share, rising to USD 775.42 Million by 2035 at an estimated 5.54% CAGR.

Multi-modal Imaging: Multi-modal Imaging is one of the most strategically important segments because researchers increasingly require complementary datasets without transferring animals through disconnected laboratory workflows. Roughly 14% of 2026 market demand is associated with multimodal systems, while approximately 55% of large imaging cores consider cross-modality registration important for advanced studies. PET/CT, SPECT/CT, PET/MRI, optical/CT, and other combinations support stronger anatomical correlation, molecular localization, and longitudinal consistency. Growth is reinforced by standardized animal beds, coordinated anesthesia, shared reconstruction software, and automated image fusion.

Multi-modal Imaging is valued at approximately USD 393.09 Million in 2026 with 14% market share and is projected to reach USD 686.80 Million by 2035, reflecting a 6.40% CAGR.

Optical Imaging: Optical Imaging remains widely used because fluorescence and bioluminescence techniques offer sensitive, comparatively accessible tools for oncology, infectious disease, gene expression, cell tracking, and therapeutic research. The segment represents approximately 11% of 2026 demand, while almost 38% of smaller biomedical laboratories favor optical imaging where high-throughput molecular screening is important. Continued improvements in detector sensitivity, spectral separation, tomography, and anatomical co-registration are improving experimental utility. Optical systems also benefit from relatively straightforward operation compared with more infrastructure-intensive imaging modalities.

Optical Imaging represents about USD 308.85 Million in 2026 and 11% market share, reaching an estimated USD 443.10 Million by 2035 at a 4.09% CAGR.

Ultrasound Imaging: Ultrasound Imaging is gaining relevance in cardiovascular research, developmental biology, oncology, vascular studies, organ function, and image-guided procedures. Approximately 9% of 2026 market demand is assigned to ultrasound, while nearly 41% of users value the modality for real-time physiological assessment without ionizing radiation. High-frequency transducers, advanced Doppler, elastography, three-dimensional imaging, and automated measurements are expanding capabilities. Equipment portability and relatively rapid acquisition can also improve utilization in laboratories where multiple experimental groups share the same imaging infrastructure.

Ultrasound Imaging is estimated at USD 252.70 Million in 2026 with 9% market share and is modeled to reach USD 420.94 Million by 2035, representing a 5.83% CAGR.

Photoacoustic Imaging: Photoacoustic Imaging combines optical contrast with ultrasound-based spatial localization, allowing researchers to investigate oxygenation, vascularity, hemoglobin-related signals, molecular probes, and tumor microenvironments. The segment represents about 5% of 2026 market demand, while approximately 28% of advanced vascular and oncology imaging groups are evaluating photoacoustic techniques as a complementary modality. Adoption is supported by expanded wavelength capability, improved laser systems, quantitative oxygen-saturation tools, and integration with high-frequency ultrasound. Its position remains smaller than established modalities but its functional information supports above-market expansion.

Photoacoustic Imaging accounts for approximately USD 140.39 Million in 2026 and 5% market share, increasing to USD 265.86 Million by 2035 at an estimated 7.35% CAGR.

Reagents: Reagents support optical probes, radiotracers, contrast agents, targeted molecular imaging, and specialized functional studies. Approximately 6% of 2026 market demand is associated with reagents, while nearly 34% of molecular imaging programs depend on study-specific contrast or labeling agents during selected protocols. Demand is influenced by experimental throughput, disease model, regulatory handling, tracer availability, and imaging modality. Growth is comparatively moderate because reagent consumption expands alongside installed equipment but remains dependent on protocol intensity and laboratory research budgets.

Reagents represent approximately USD 168.47 Million in 2026 and 6% market share, reaching USD 221.55 Million by 2035 at an estimated 3.09% CAGR.

Services: Services include installation, preventive maintenance, calibration, application support, training, workflow optimization, and selected image-analysis assistance. Services account for approximately 4% of 2026 market demand, while about 31% of sophisticated buyers place greater weight on service response and application expertise when comparing technically similar systems. As laboratories operate more complex multimodal platforms, dependable technical support becomes increasingly important for protecting research schedules. Remote diagnostics, software maintenance, training programs, and protocol development can also strengthen long-term supplier relationships.

Services are estimated at USD 112.31 Million in 2026 with 4% market share and are projected to reach USD 155.08 Million by 2035, representing an estimated 3.65% CAGR.

By Application

Hospital: Hospitals with academic affiliations, translational research programs, and specialized medical research institutes represent a substantial application group. Approximately 36% of 2026 market activity is attributed to hospital-linked research environments, while nearly 48% of these facilities prioritize imaging methods that can bridge experimental and clinical research questions. Their workloads frequently include oncology, neurology, cardiovascular disease, regenerative medicine, and therapeutic-response studies. Shared imaging cores, multidisciplinary research teams, and access to clinical imaging expertise support adoption, although capital governance can make procurement cycles comparatively structured.

Hospital applications represent approximately USD 1010.79 Million in 2026 and 36% market share, reaching USD 1506.53 Million by 2035 at an estimated 4.53% CAGR.

Diagnostics Center: Diagnostics centers in this market include specialized translational imaging facilities and research-oriented diagnostic laboratories operating advanced imaging infrastructure. The segment accounts for approximately 29% of 2026 market demand, while about 42% of specialized centers emphasize quantitative image analysis and standardized acquisition protocols. Such facilities often operate several modalities and serve multiple internal or external research groups, making instrument utilization, service reliability, and protocol repeatability critical. Demand also benefits from increased molecular imaging, biomarker validation, and companion-diagnostic research.

Diagnostics Center applications account for approximately USD 814.25 Million in 2026 with 29% market share and are projected to reach USD 1284.98 Million by 2035 at a 5.20% CAGR.

Others: Other applications include pharmaceutical companies, biotechnology developers, contract research organizations, universities, veterinary research groups, and independent biomedical laboratories. Together they represent approximately 35% of 2026 demand, while nearly 53% of pharmaceutical and contract research users prioritize longitudinal imaging when evaluating therapeutic candidates. This category is expected to gain share because outsourced drug development, specialized imaging services, molecular therapeutics, and academic-industry partnerships continue expanding the number of organizations that require sophisticated imaging. Flexible platforms and outsourced imaging models make this group especially responsive to new technology.

Other applications represent approximately USD 982.71 Million in 2026 with 35% market share and are projected to reach USD 1639.46 Million by 2035 at an estimated 5.85% CAGR.

Preclinical Imaging Market Regional Outlook

The Preclinical Imaging Market shows distinct regional adoption patterns shaped by pharmaceutical research intensity, university infrastructure, government science funding, radiopharmaceutical capability, and installed imaging capacity. North America remains the largest regional market with approximately 38% share, while Asia-Pacific accounts for about 25% and is positioned for faster expansion as biomedical research infrastructure grows. Europe maintains a substantial installed base supported by pharmaceutical development, molecular imaging networks, and public research institutes. Middle East & Africa remains comparatively smaller but is developing through research hospitals and national life-science programs. Regional competition increasingly depends on application support, distributor strength, scanner serviceability, regulatory knowledge, and the ability to deliver integrated research workflows rather than equipment alone.

North America

North America leads the Preclinical Imaging Market because of its concentration of pharmaceutical companies, biotechnology clusters, university medical centers, contract research organizations, and advanced imaging cores. The region represents approximately 38% of global demand in 2026, while close to 51% of large preclinical facilities in the region operate multiple imaging modalities. U.S. institutions dominate regional activity, with Canada contributing through academic imaging, oncology research, neuroscience, and translational medicine. Buyers increasingly favor high-utilization systems, multimodal compatibility, quantitative software, reliable service coverage, and technologies that support repeated longitudinal measurements. Investment in radiopharmaceuticals and molecular therapeutics further strengthens PET/SPECT and multimodal demand.

North America is estimated at USD 1066.94 Million in 2026, representing 38% market share, and is projected to reach approximately USD 1617.31 Million by 2035 as its share moderates to about 36.5%.

Europe

Europe remains an established preclinical imaging region supported by pharmaceutical research, university hospitals, national research institutes, and molecular imaging collaborations. Approximately 27% of global market demand originates in Europe, while about 46% of major regional imaging laboratories emphasize multimodal or cross-platform research capability. Germany, the United Kingdom, France, Italy, the Netherlands, Switzerland, and Nordic research environments contribute meaningfully to equipment demand. European laboratories frequently prioritize reproducibility, animal-welfare refinement, radiotracer research, and centralized shared-core infrastructure. Growth opportunities are strongest where aging systems require replacement and research organizations expand theranostic, oncology, neurological, and cardiovascular imaging programs.

Europe represents approximately USD 758.09 Million in 2026 and 27% market share, with the regional market modeled to reach USD 1129.90 Million by 2035 and approximately 25.5% global share.

Asia-Pacific

Asia-Pacific is the most dynamic regional growth environment as China, Japan, South Korea, India, Australia, and other research markets expand biomedical infrastructure. The region represents approximately 25% of global demand in 2026, while nearly 43% of newly established sophisticated imaging facilities favor modular systems that can expand with research workloads. Pharmaceutical development, government-backed biomedical science, university research capacity, oncology studies, regenerative medicine, and molecular imaging are supporting adoption. Buyers remain price-conscious in several markets, but demand is shifting toward higher-resolution systems and integrated platforms where research programs require internationally comparable data and advanced quantitative analysis.

Asia-Pacific accounts for approximately USD 701.94 Million in 2026 and 25% market share and is projected to reach USD 1262.83 Million by 2035, increasing its global share to approximately 28.5%.

Middle East & Africa

Middle East & Africa represents an emerging Preclinical Imaging Market centered on major academic hospitals, national research institutes, and life-science investment programs. The region accounts for approximately 6% of global demand in 2026, while close to 32% of advanced installations are concentrated in a limited number of research hubs. Gulf countries are strengthening biomedical and translational research capacity, whereas South Africa and selected North African institutions support academic and medical imaging programs. Market development depends heavily on distributor capability, training, service access, facility readiness, and funding continuity. Compact imaging platforms and shared research infrastructure can improve adoption where utilization does not support large independent modality suites.

Middle East & Africa represents approximately USD 168.47 Million in 2026 and 6% market share, with modeled market size reaching USD 265.86 Million by 2035 while retaining approximately 6% global share.

List of Key Preclinical Imaging Market Companies Profiled

Investment Analysis and Opportunities

Investment in the Preclinical Imaging Market is increasingly directed toward multimodal platforms, molecular imaging, quantitative software, photoacoustic systems, and research infrastructure capable of supporting longitudinal studies. Approximately 47% of strategic equipment investment is influenced by the ability to extend a platform through software, detector, probe, or modality upgrades, while nearly 35% of buyers prioritize systems that can support several disease areas rather than one specialized workflow. This favors modular product architectures and service models that reduce the risk of technological obsolescence. Pharmaceutical companies and contract research organizations represent attractive investment channels because imaging can support candidate selection, pharmacokinetics, biodistribution, toxicity research, and therapeutic-response assessment across development stages.

Opportunity is also expanding around software and workflow productivity. Nearly 44% of high-throughput research facilities are increasing interest in automated reconstruction, segmentation, registration, or quantitative analysis, while approximately 31% consider centralized data management increasingly important. Investors therefore have exposure not only to scanner hardware but also to analysis software, imaging reagents, radiotracer workflows, accessories, anesthesia systems, service contracts, and outsourced preclinical imaging. Asia-Pacific infrastructure development adds another growth avenue as laboratories upgrade from standalone instruments to internationally competitive shared-core environments. Companies that combine strong technology with application support and service coverage are positioned more favorably than suppliers competing primarily on equipment specifications.

New Products Development

New product development in preclinical imaging is concentrated on higher sensitivity, multimodality, quantitative reconstruction, workflow automation, compact system design, and improved physiological information. Approximately 53% of next-generation premium platform development is oriented toward either multimodal integration or improved compatibility with complementary imaging systems, while nearly 38% emphasizes faster reconstruction and automated analysis. In MRI, development priorities include higher field performance, advanced coils, functional imaging, spectroscopy, and hyperpolarized research. Nuclear imaging suppliers are improving detector sensitivity, isotope flexibility, simultaneous or coordinated PET/SPECT workflows, and CT or MRI integration. Optical platforms are advancing detector sensitivity and tomography, while ultrasound systems continue moving toward ultra-high-frequency imaging, elastography, and sophisticated vascular measurements.

Photoacoustic imaging is an especially active innovation area because new laser architectures, expanded wavelengths, and improved oxygenation quantification can create functional information beyond conventional ultrasound. Approximately 26% of high-end ultrasound research users are evaluating photoacoustic extensions, while 34% of multimodal buyers consider integrated animal handling a meaningful product-selection advantage. Product development is consequently becoming less centered on isolated scanner performance and more focused on the complete experimental pathway: animal preparation, acquisition, reconstruction, quantitative analysis, data fusion, and study reproducibility. Vendors capable of simplifying these steps can improve adoption even when competing systems offer comparable nominal imaging resolution.

Recent Developments

• June 2025– VisualSonics Inc. (Fujifilm) expands photoacoustic imaging with the Vevo F2 LAZR-X20: Fujifilm VisualSonics introduced the Vevo F2 LAZR-X20 platform for multimodal preclinical ultrasound and photoacoustic imaging, targeting applications including oncology, cardiovascular research, neurobiology, and molecular biology. The development reinforces a segment in which analyst models indicate photoacoustic imaging could expand its market share from roughly 5% toward 6% over the forecast period as researchers demand richer functional and oxygenation measurements alongside high-resolution ultrasound.

• May 2025– MR Solutions advances integrated high-field molecular imaging: MR Solutions reported installation of a 7T preclinical SPECT/MR system with a PET insert at Houston Methodist, demonstrating the market's movement toward highly integrated research environments. Such systems address laboratories seeking anatomical and molecular information within coordinated workflows. Multimodal imaging is modeled to increase from approximately 14% of market demand to 15.5%, reflecting growing interest in platforms that reduce animal transfers and improve cross-modality alignment.

• April 2025– Bruker introduces dissolution DNP technology for hyperpolarized MRI research: Bruker announced a dissolution dynamic nuclear polarization system following its first customer installation at UCSF, supporting hyperpolarized carbon-13 MRI research in areas such as cancer evaluation and treatment response. The technology reflects increasing demand for functional and metabolic imaging beyond conventional anatomy. MRI retains approximately 18% modeled market share while higher-value functional techniques could raise utilization within advanced translational laboratories.

• February 2024– Bruker broadens optical imaging through Spectral Instruments Imaging acquisition: Bruker acquired Spectral Instruments Imaging to extend its preclinical portfolio into in-vivo bioluminescence, fluorescence, and X-ray imaging. The transaction strengthened Bruker's ability to offer complementary imaging technologies within a broader preclinical platform strategy. Optical imaging represents approximately 11% of the modeled 2026 market, and portfolio integration can improve supplier competitiveness among the 56% of advanced research programs that increasingly value interoperability across imaging techniques.

• February 2024– MILabs supports deployment of an ultra-high-performance PET-CT research platform: MILabs highlighted deployment of a new U-PET/CT system at the Beckman Institute, reinforcing demand for integrated molecular and anatomical imaging in research laboratories. PET/SPECT imaging accounts for an estimated 17% of market demand, while multimodal research configurations continue gaining importance as facilities seek quantitative tracer information and anatomical localization from coordinated workflows. The development illustrates ongoing replacement of older imaging infrastructure with higher-performance integrated systems.

Report Coverage

The Preclinical Imaging Market analysis covers CT Imaging, MRI Imaging, PET/SPECT Imaging, Multi-modal Imaging, Optical Imaging, Ultrasound Imaging, Photoacoustic Imaging, Reagents, and Services. These categories collectively represent 100% of the modeled technology market, with MRI contributing approximately 18% and PET/SPECT accounting for 17% of 2026 demand. Application coverage includes Hospital, Diagnostics Center, and Others, with the latter incorporating pharmaceutical companies, biotechnology organizations, contract research organizations, universities, and specialized research laboratories. The analysis evaluates technology adoption, workflow requirements, purchasing behavior, multimodal integration, software development, service considerations, and the operational factors influencing scanner utilization.

Regional coverage evaluates North America, Europe, Asia-Pacific, Middle East & Africa, with Latin America incorporated in the overall regional-share assessment. North America represents approximately 38% of modeled 2026 demand, while Asia-Pacific accounts for about 25% and is expected to gain relative share through expanding biomedical research infrastructure. Competitive assessment includes Bruker Corporation, Siemens A.G., General Electric (GE), TriFoil Imaging, PerkinElmer, Inc., VisualSonics Inc. (Fujifilm), Mediso Ltd., Agilent Technologies, MILabs B.V., MR Solutions, and Molecubes. The report framework also evaluates market drivers, opportunities, restraints, challenges, investment patterns, technology development, application shifts, and strategic supplier positioning across the preclinical imaging ecosystem.